Kura Oncology (NASDAQ:KURA – Get Free Report) and Sagimet Biosciences (NASDAQ:SGMT – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends and earnings.
Profitability
This table compares Kura Oncology and Sagimet Biosciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Kura Oncology | -384.30% | -207.18% | -45.17% |
| Sagimet Biosciences | N/A | -31.96% | -30.57% |
Analyst Ratings
This is a breakdown of current ratings for Kura Oncology and Sagimet Biosciences, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Kura Oncology | 1 | 1 | 11 | 0 | 2.77 |
| Sagimet Biosciences | 2 | 1 | 9 | 0 | 2.58 |
Kura Oncology presently has a consensus price target of $25.35, suggesting a potential upside of 248.73%. Sagimet Biosciences has a consensus price target of $26.63, suggesting a potential upside of 170.40%. Given Kura Oncology’s stronger consensus rating and higher possible upside, analysts plainly believe Kura Oncology is more favorable than Sagimet Biosciences.
Risk and Volatility
Kura Oncology has a beta of 0.56, meaning that its share price is 44% less volatile than the S&P 500. Comparatively, Sagimet Biosciences has a beta of 3.43, meaning that its share price is 243% more volatile than the S&P 500.
Institutional and Insider Ownership
87.9% of Sagimet Biosciences shares are held by institutional investors. 7.6% of Kura Oncology shares are held by insiders. Comparatively, 11.5% of Sagimet Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Valuation and Earnings
This table compares Kura Oncology and Sagimet Biosciences”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Kura Oncology | $77.22 million | 8.37 | -$278.67 million | ($3.37) | -2.16 |
| Sagimet Biosciences | $2.00 million | 306.14 | -$51.04 million | ($1.28) | -7.70 |
Sagimet Biosciences has lower revenue, but higher earnings than Kura Oncology. Sagimet Biosciences is trading at a lower price-to-earnings ratio than Kura Oncology, indicating that it is currently the more affordable of the two stocks.
Summary
Sagimet Biosciences beats Kura Oncology on 9 of the 14 factors compared between the two stocks.
About Kura Oncology
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.
About Sagimet Biosciences
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company’s lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
